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This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across
a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low
income countries (MLICs), with robustness checks to other therapeutic categories and other countries.
We examine effects of per capita income, income dispersion, number and type of therapeutic and generic
competitors, and whether the drugs are sold to retail pharmacies vs. tendered procurement by NGOs.
The cross-national income elasticity of prices is 0.4 across high and low income countries, but is only
0.15 between MLICs, implying that drugs are least affordable relative to income in the lowest income
countries. Within-country income inequality contributes to relatively high prices in MLICs. Number
of therapeutic and generic competitors only weakly affects prices to retail pharmacies, plausibly because
uncertain quality leads to competition on brand rather than price. Tendered procurement attracts multi-national
generic suppliers and significantly reduces prices for originators and generics, compared to prices
to retail pharmacies.
Patricia M. Danzon








































































































































































































































ln               IMS*GEN     GPRM*ORIG     GPRM*GEN                 *      




















































































































































































































































































































































































































mean stddev mean stddev  mean  stddev
   
Retail (IMS) sample   
Log per capita income  9.76 1.00 8.24 0.65 8.25  0.64
Raw per capita income  24,318 14,082 4,610 2,812  4,644  2,802
Log annual treatment cost  7.01 1.81 5.45 1.57 5.43  1.58
Raw annual treatment cost  2,974 3,858 574 827 570  822
HIV prevalence per 100K  7.93 23.70 25.41 42.42  25.02  42.17
Gini coefficient  34.37 13.12 40.17 18.37  40.17  18.22
Gini coefficient missing flag  0.07 0.25 0.13 0.33 0.12  0.33
Tender gen. manufs. in class‐ctry.  0.39 1.17 1.55 1.90 1.53  1.90
Retail gen. manufs. In class‐ctry.  9.70 20.53 26.18 34.05  25.77  33.92
Originator manufs. in class‐ctry.  2.72 1.62 3.01 1.87 2.97  1.88
Originator present in country  0.85 0.36 0.78 0.42 0.78  0.42
Generic present in country  0.50 0.50 0.82 0.38 0.82  0.38
Form = *Not* oral solid  0.17 0.38 0.16 0.37 0.16  0.37
Observations (n)†  5,790 1,468 1,493
 
Tendered (GPRM) sample 
Log per capita income  7.70 0.98 8.10 0.79 8.08  0.61
Raw per capita income  3,467 3,451 4,360 2,990  3,867  2,291
Log annual treatment cost  5.14 1.42 5.35 1.37 5.18  1.46
Raw annual treatment cost  561 2,347 547 1,178  634  2,704
HIV prevalence per 100K  29.23 49.26 31.47 42.14  26.21  55.88
Gini coefficient  37.39 19.14 43.90 14.15  38.42  17.74
Gini coefficient missing flag  0.17 0.38 0.05 0.22 0.13  0.34
Tender gen. manufs. in class‐ctry.  2.11 1.88 3.18 2.55 2.11  1.90
Retail gen. manufs. In class‐ctry.  0.73 6.04 5.74 16.05  1.13  7.48
Originator manufs. in class‐ctry.  1.18 1.12 2.19 1.44 1.23  1.19
Originator present in country  0.52 0.50 0.72 0.45 0.52  0.50
Generic present in country  0.79 0.41 0.85 0.35 0.79  0.40
Form = *Not* oral solid  0.24 0.43 0.25 0.43 0.25  0.43


































































Observations  11695 2222 5314










      IMS Generic  IMS Brand  GPRM Generic  GPRM Brand 
Log per capita GNI 
‐0.621** 0.102 0.0476  0.325***
[0.269] [0.345] [0.0321]  [0.0580]
Gini coefficient  0.0750** 0.0474** ‐0.00153  ‐0.00324
[0.0258] [0.0159] [0.00326]  [0.00580]
Gini coefficient missing 
indicator 
‐0.398 0.466 0.0773  0.0607
[0.421] [0.490] [0.0594]  [0.131]
HIV prevalence per 1K 
‐0.0114 ‐0.0183*** 0.00024  ‐0.00215***





















  Tender generic class count  ‐0.0477 ‐0.126*** 0.00324  ‐0.0265
[0.0291] [0.0350] [0.00948]  [0.0159]
Retail generic class count  ‐0.0124*** ‐0.0125*** 0.0102  0.00962
[0.00356] [0.00193] [0.00986]  [0.0144]
Originator class count  ‐0.00757 0.142*** 0.0075  ‐0.0155





Non‐oral solid flag  1.700*** 1.431*** 0.00866  ‐0.285***










Supplier: UNICEF      ‐0.0741  0.217**
[0.0520]  [0.0862]
Supplier: GlobalFund      0.202***  0.239**
[0.0578]  [0.0920]
Supplier: IDA      0.176***  0.408***
[0.0516]  [0.105]
Supplier: MissionPharma      0.124  ‐0.0977
[0.0762]  [0.128]
Molecule  and year fixed effects  X X X X
Constant  6.852** 3.071 4.272***  3.780***
[2.850] [3.141] [0.346]  [0.500]
Observations  741 719 3890  2088


















   Generics  Originators Generics Originators Generics  Originators
Log per capita GNI  ‐0.591*  0.126 ‐0.274 ‐0.944*** ‐0.269  ‐0.940***
[0.272]  [0.341] [0.303] [0.160] [0.287]  [0.125]
Gini coefficient  0.0738**  0.0502** 0.105** 0.135*** 0.107***  0.139***
[0.0259]  [0.0185] [0.0340] [0.0149] [0.0333]  [0.0119]
Gini missing 
indicator 
‐0.54  0.145 ‐0.825 ‐2.052*** ‐0.804  ‐2.055***
[0.393]  [0.583] [0.533] [0.260] [0.512]  [0.215]
HIV prevalence per 
1K 
‐0.0108  ‐0.0199*** ‐0.0191** ‐0.0242*** ‐0.0192**  ‐0.0244***
[0.00835]  [0.00288] [0.00762] [0.00266] [0.00743]  [0.00207]
Generic class count  ‐0.0123***  ‐0.0134*** ‐0.00405*** ‐0.00227*** ‐0.00442***  ‐0.00203***
[0.00331]  [0.00284] [0.000846] [0.000675] [0.000966]  [0.000585]
Originator class 
count 
0.00177  0.179*** 0.00715 ‐0.0362 ‐0.0161  ‐0.0566**
[0.0944]  [0.0541] [0.0301] [0.0290] [0.0235]  [0.0232]
Originator mol. flag  0.165  N/A ‐0.11 N/A ‐0.0698  N/A
[0.117]  N/A [0.126] N/A [0.129]  N/A
Generic molecule 
flag 
N/A  ‐0.0657 N/A ‐0.113 0  ‐0.106
N/A  [0.150] N/A [0.0921] [0]  [0.0801]
Non‐oral solid flag 
1.685***  1.501*** 0.689*** 0.621*** ‐0.488**  ‐0.166
[0.294]  [0.227] [0.169] [0.100] [0.161]  [0.148]
OTC flag  1.057*  0.887 0.505 0.631*** 0.513  0.774***
[0.526]  [0.510] [0.620] [0.167] [0.608]  [0.126]
Molecule and year 
F E   X  X   X   X  X  X  
Constant  6.591*  2.722 ‐3.036 2.288* ‐2.147  2.611***
[3.004]  [2.935] [2.828] [1.090] [2.668]  [0.715]
Observations  766  743 9207 4600 7597  3942
R‐squared  0.847  0.773 0.764 0.804 0.76  0.793
 
†Significance levels: ***=p<0.01, **=p<0.05, *=p<0.1.  Robust standard errors adjusted for 37 
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Observations  11695 2222 5314
R‐squared  0.797 0.663 0.651
† Significance levels:  ***=p<0.01, **=p<0.05, *=p<0.1.  Robust standard errors adjusted for 37 clusters in 
country in brackets.   
‡ Implied effects for indicator variables including variance correction (see Kennedy 1981) reported in bottom 
line. 